Stay updated with breaking news from Clinical Development Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ...
Previous Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates Cash position of €6.8...
Data readout from Phase 3 clinical trial in the People's Republic of China evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial...
Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways in neurodegenerative diseases Expansion of COYA 302 into...
Entered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian marketsPhase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at the European Society of Cardiology Congress 2023 with simultaneous publication in JAMA Cardiology Topline data announced from Phase 3 trial of TP-03 in Chinese Demodex blepharitis patientsCash, cash equivalents and marketable securities of $252.2 million as of September 30, 2023Strategic review ongo